Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a regenerative and aesthetic medicine company whose news flow centers on its recombinant human collagen (rhCollagen) platform, 3D bioprinting activities and medical aesthetics programs. The company regularly issues updates on its rhCollagen-based BioInk products for 3D bioprinting of tissues and organs, tissue repair solutions and aesthetics-focused product candidates.
Investors following CLGN news can expect coverage of financial results reported via quarterly updates, including revenue trends from business collaborators, BioInk sales and tendon repair and wound healing products. CollPlant also reports on clinical and non-clinical milestones for its photocurable dermal and soft tissue filler program, regenerative breast implant development and its collaboration with AbbVie and Allergan on dermal and soft tissue fillers.
Another key news theme is scientific and research collaborations. CollPlant highlights studies such as the Technion – Israel Institute of Technology comparison of its Collink.3D bioink with Matrigel, and Mayo Clinic’s work on a fully humanized 3D bioprinted skin model using plant-derived rhCollagen. These items illustrate how the company’s materials are used in tissue engineering, disease modeling and non-animal alternatives for preclinical research.
Corporate and commercial updates are also frequent, including announcements about expansion of Vergenix STR tendon-repair product distribution in Europe, establishment of a North American logistics center for rhCollagen and BioInk distribution, and participation in industry conferences and investor events. For readers tracking developments in rhCollagen-based biomaterials, 3D bioprinting and aesthetic medicine, the CLGN news page provides an ongoing stream of company-generated information and regulatory disclosures.
CollPlant Biotechnologies (Nasdaq: CLGN) announced the release of its financial results for the first quarter of 2024 on May 29, 2024, before U.S. market opening. The company will host a conference call and webcast the same day at 10:00 a.m. EDT to discuss these results and provide corporate updates.
U.S. investors can dial 1-877-407-9716, international investors can call 1-201-493-6779, and Israeli investors can dial 1-809-406-247 using Conference ID 13745964. Participants can avoid long wait times by using the Call me™ feature available 15 minutes prior to the call.
A live listen-only webcast will be available, with a replay accessible on the company's website for a period. Questions for management can be submitted via email to Dan Ferry at LifeSci Advisors up to 24 hours before the event.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.